Aura Biosciences is laying off 20% of its staff to concentrate on a single experimental eye cancer treatment. This strategic shift aims to reduce operating costs and extend the company's cash runway into 2029. The company is deprioritizing its bladder cancer program to focus resources on its lead dr-g candidate for choroidal melanoma. This restructuring includes leadership changes and follows a recent increase in authorized common stock. These layoffs are part of a broader trend of workforce reductions within the Massachusetts biotech sector.
Boston, Massachusetts
https://hoodline.com/2026/08/cambridge-eye-cancer-biotech-aura-cuts-20-of-staff-to-fund-late-stage-trial/